NO-NSAIDs and cancer: promising novel agents.
Three potential applications of NO-donating NSAIDs in human cancer include their use: as chemopreventive agents; against already developed cancers (chemotherapy); and for the control of cancer symptoms, notably cancer pain. The evidence to date of greater safety and enhanced efficacy of NO-donating NSAIDs underscores their potential to prevent colon cancer and overcome the limitations of traditional NSAIDs. NO-donating NSAIDs affect several pathways critical to colon carcinogenesis and this may explain in part their greater efficacy in colon cancer prevention as assessed in preclinical models.
Rigas
B
B
American Health Foundation, 1 Dana Road, Valhalla, NY 10595, USA. brigas@ahf.org
Kalofonos
H
H
Lebovics
E
E
Vagenakis
A G
AG
D032761:Animal Experimentation; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001241:Aspirin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D006801:Humans; D066298:In Vitro Techniques; D009288:Naproxen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; C111751:naproxen-n-butyl nitrate; C098312:nitroxy-butyl-acetylsalicylic acid; D009569:Nitric Oxide; D009288:Naproxen; C102148:nitroaspirin; D001241:Aspirin